1 Top Penny Stock to Watch Now This small-cap biotech is chasing a big breakthrough in 2026. Barchart · Jan 17
BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients BioXcel Therapeutics, Inc. (NASDAQ:BTAI) on Wednesday released topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial, which demonstrated that BXCL501 had continued effects and consistent benefit with repeat dosing. Benzinga · Sep 10, 2025
EXCLUSIVE: August's 20 Most-Searched Tickers On Benzinga Pro – Where Do Opendoor, Palantir, BitMine Immersion, Apple Stock Rank? Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. Benzinga · Sep 2, 2025
BioXcel Seeks FDA Label Expansion For Schizophrenia Treatment BioXcel Therapeutics Inc. (NASDAQ:BTAI) announced that its SERENITY At-Home Phase 3 trial of BXCL501—its sublingual dexmedetomidine film for acute agitation in bipolar disorder or schizophrenia—met its primary endpoint. Benzinga · Aug 27, 2025
BioXcel Therapeutics (BTAI) Stock Is Surging Monday: What's Going On? BioXcel Therapeutics Inc (NASDAQ:BTAI) shares are trading higher. The AI biopharmaceutical company on Monday announced positive meeting comments from the U.S. Food and Drug Administration (FDA). Benzinga · Aug 18, 2025
3 Supercharged Stocks Flashing Strong Momentum Signals Several stocks have shown strong momentum in recent sessions as broader markets charge to all-time highs. Here’s a look at some standout momentum movers that are just starting to pick up steam. Benzinga · Aug 13, 2025
BioXcel Therapeutics (BTAI) Stock Is Extremely Volatile Today: What's Going On? Shares of BioXcel Therapeutics Inc (NASDAQ:BTAI) are trading higher Tuesday morning, reversing sharply following earlier weakness, after the company announced its financial results for the second quarter. Here’s what investors need to know. Benzinga · Aug 12, 2025